ABSTRACT

Bioanalysis is the method used to determine the concentration of drugs, their metabolites in the biological matrices such as blood plasma, serum, cerebrospinal fluid, urine and saliva. Bioanalytical method employed for the quantitative determination of drugs and their metabolites in biological fluids plays a significant role in the evaluation and interpretation of bioequivalence, pharmacokinetics and toxic kinetic studies. For various types of drug approval processes at different timings to regulate and harmonize bioanalytical method development and validation is required. Gas chromatography, highpressure liquid chromatography, LC and GC, combined with mass spectrometric (MS) procedures such as LC-MS, LC-MS-MS, GC-MS, and GC-MS-MS are used for quantitative analysis. Techniques such as high pressure liquid chromatography (HPLC) and liquid chromatography coupled with double mass spectrometry (LCMS-MS) can be used for the bioanalysis of drugs in body. Empagliflozin(EMPA) is an orally active, potent and selective inhibitor of sodium glucose cotransporter 2 (SGLT2), currently in clinical development to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM). SGLT2 inhibitors, including empagliflozin, are the first pharmacological class of antidiabetes agents to target the kidney in order to remove excess glucose from the body and, thus, offer new options for T2DM management. SGLT2 inhibitors exert their effects independently of insulin. This review covers most recent bioanalytical methods such as various chromatographic methods and other methods for determination of Empagliflozin in various pharmaceutical dosage forms were reported. Keywords: Antidiabetic drug, Empagliflozin (EMPA), Bioanalytical methods
Publication date: 01/05/2022

https://ijbpas.com/pdf/2022/May/MS_IJBPAS_2022_6071.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.5.6071